Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Mitogens and the Cell Cycle

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

An anti-PMEL antibody-drug conjugate with a G<sub>q/1</sub><sub>1</sub> inhibitor payload in GNAQ/GNA11-mutant melanomas: a phase 1 trial.

Nature medicine·2026

Same author

Identification of cellular intermediates unveils unique enzymes for flagellar glycan biosynthesis in <i>Clostridioides difficile</i>.

Proceedings of the National Academy of Sciences of the United States of America·2026

Same author

Blood-based kinase activity profiling to predict response to immune checkpoint inhibitors in patients with advanced stage NSCLC: the prospective IOpener study.

Journal for immunotherapy of cancer·2026

Same author

Dual mechanism of immune escape shapes the genetic and immunogenic landscape of mismatch repair-deficient colorectal tumours.

Gut·2026

Same author

Spatial Analysis Reveals Gene Expression and Microenvironmental Changes in the Transition of Nevus to Melanoma.

Cancer research·2026

Same author

Dissection of the T cell infiltrate in mouse pancreatic tumors reveals an extensive and diverse tumor-reactive T cell repertoire.

Science advances·2026

Search research articles

Related Experiment Video

Updated: Jul 20, 2025

A 3D Organotypic Melanoma Spheroid Skin Model

A 3D Organotypic Melanoma Spheroid Skin Model

Published on: May 18, 2018

Neoantigen Targetability in Progressive Advanced Melanoma.

Jitske van den Bulk¹, Els M E Verdegaal², Manon van der Ploeg¹

¹Department of Pathology, Leiden University Medical Center, Leiden, the Netherlands.

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research

|August 4, 2023

Summary

Advanced melanoma metastases maintain T-cell infiltration and neoantigen targets, supporting ongoing T-cell immunotherapy. Tumors retain antigen presentation and T-cell recognition, indicating continuous therapeutic potential.

More Related Videos

Spatial and Temporal Control of Murine Melanoma Initiation from Mutant Melanocyte Stem Cells

Spatial and Temporal Control of Murine Melanoma Initiation from Mutant Melanocyte Stem Cells

Published on: June 7, 2019

Using X-ray Crystallography, Biophysics, and Functional Assays to Determine the Mechanisms Governing T-cell Receptor Recognition of Cancer Antigens

Using X-ray Crystallography, Biophysics, and Functional Assays to Determine the Mechanisms Governing T-cell Receptor Recognition of Cancer Antigens

Published on: February 6, 2017

Related Experiment Videos

Last Updated: Jul 20, 2025

A 3D Organotypic Melanoma Spheroid Skin Model

A 3D Organotypic Melanoma Spheroid Skin Model

Published on: May 18, 2018

Spatial and Temporal Control of Murine Melanoma Initiation from Mutant Melanocyte Stem Cells

Spatial and Temporal Control of Murine Melanoma Initiation from Mutant Melanocyte Stem Cells

Published on: June 7, 2019

Using X-ray Crystallography, Biophysics, and Functional Assays to Determine the Mechanisms Governing T-cell Receptor Recognition of Cancer Antigens

Using X-ray Crystallography, Biophysics, and Functional Assays to Determine the Mechanisms Governing T-cell Receptor Recognition of Cancer Antigens

Published on: February 6, 2017

Area of Science:

Immunology
Oncology
Genomics

Background:

T-cell infiltration and neoantigen availability are key for cancer immunotherapy success.
Understanding these factors in advanced melanoma is crucial for optimizing T-cell-based treatments.

Purpose of the Study:

To investigate neoantigen targetability in advanced progressive melanoma.
To explore the potential for sustained T-cell-based immunotherapy in melanoma metastases.

Main Methods:

Analysis of sequential melanoma metastases from eight patients.
Assessment of antigen-presenting capacity, T-cell infiltration, and neoantigen landscape via IHC, flow cytometry, immunofluorescence, and sequencing.
Evaluation of tumor recognition by autologous T cells through coculture assays.

Main Results:

Similar T-cell infiltration was observed in early and late metastatic lesions.
Melanoma cell lines from both early and late metastases were recognized by autologous T cells.
The neoantigen landscape was dynamic, but the neoantigen load remained stable between paired lesions.

Conclusions:

Advanced melanoma metastases retain antigen-presenting capacity and T-cell infiltration.
A stable neoantigen load supports sustained T-cell recognition in progressing melanoma.
Findings support continued exploration of neoantigen-specific T-cell therapies for advanced melanoma.